|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | NuVasive, Inc.(NASDAQ:NUVA), a developer of products for minimally disruptive surgical treatments for the spine. |
|---|---|
| Transferring Party | Cervical replacement Technology from Pearsalls Limited, a U.K.-based medical device company privately owned by AMI Holdings, Inc., a platform company of RoundTable Healthcare Partners. |
| Sector | Medical Devices |
| Date | August 4, 2005 |
| Analysis Offers NuVasive a market-first cervical nucleus-like device designed to preserve motion in the cervical region of the spine and fill the gap between pre-surgical treatment and total disc replacement or spine fusion. Deal valued at $12 million in cash and stock, with milestone payments that could total $31.5 million (relating to FDA approval). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |